Therapeutic effect of bisoprolol combined with salvianolate on patients with coronary heart disease after PCI

doi:10.12092/j.issn.1009-2501.2019.04.014

Abstract

Abstract:

AIM: To analyze the influence of bisoprolol combined with salvianolate on the inflammatory microenvironment and hemorheology indexes of patients with coronary heart disease after percutaneous coronary intervention (PCI). METHODS: Totally 120 cases of patients with coronary heart disease treated in our hospital from July, 2015 to May, 2017 who underwent PCI were randomly divided into control group and experimental group according to computer-generated number table method, with 60 cases in each group. The patients in control group were given conventional treatment, and the patients in experimental group were administered bisoprolol combined with salvianolate on that basis. The inflammatory microenvironment and hemorheology indexes of the patients in both groups were comparatively analyzed. RESULTS:After treatment, the levels of hypersensitive C-reactive protein (hs-CRP), TNF-α, lipoprotein-associated phospholipase A2 (Lp-PLA2), soluble intercellular adhesion molecule-1 (sICAM-1), Toll-like receptors 4 (TLR4) and soluble vascular cell adhesionmolecula-1 (sVCAM-1) in experimental group were all lower than those in control group, with statistically significant (P＜0.05). The hematokrit, whole blood high shear viscosity, fibrinogen, whole blood low shear viscosity, erythrocyte aggregation index as well as plasma viscosity in experimental group were all lower than those in control group, while the erythrocyte deformation index was higher, with statistically significant (P＜0.05). Both the left ventricular end diastolic diameter and the left ventricular end systolic diameter in experimental group were lower than those in control group, whereas the left ventricular ejection fraction showed the opposite response, with statistically significant (P＜0.05). The levels of monocyte chemoattractant protein-1 (MCP-1), growth differentiation factor-15 (GDF-15) and lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in the experimental group were all lower than those in control group, while the level of visceral adipose tissue- derived serine protease inhibitor (Vaspin) in the experimental group was higher than that of the control group, with statistically significant (P＜0.05). CONCLUSION:The combination of bisoprolol and salvianolate is conducive to improving the inflammatory microenvironment, hemorheology and cardiac function indexes of patients with coronary heart disease after PCI, and is worthy to be popularized.

Key words: bisoprolol, salvianolate, coronary heart disease, PCI, inflammatory microenvironment, hemorheology indexes

CLC Number:

R541.4

CHEN Miao, ZHANG Xinjin, MENG Hongli, YANG Bei, SONG Lijuan, ZOU Chuannan, GUAN Yingxia. Therapeutic effect of bisoprolol combined with salvianolate on patients with coronary heart disease after PCI[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 451-457.

References

［1］靳海斌. PCI介入治疗对冠心病患者左心室局部及整体收缩功能的影响［J］. 中国循证心血管医学杂志, 2016, 8(9): 1084-1086.
［2］叶沃若, 王俊, 刘书宇. 比索洛尔对急性冠脉综合征患者急诊PCI术后QRS-T夹角的影响［J］. 中国药房, 2016, 27(33): 4624-4627.
［3］朱振宇, 李永东. 丹参多酚酸盐对冠心病的作用机制与临床效果［J］. 医学综述, 2017, 23(5): 948-952.
［4］M·索科洛夫, M·B·麦克尔罗伊, M·D·切特林. 临床心脏病学［M］. 上海医科大学出版社, 1992.
［5］Zanfina A, Kumar P, Danny L. Cost-effectiveness of eplerenone compared to usual care in patients with chronic heart failure and NYHA class II symptoms, an Australian perspective［J］. Medicine, 2016, 95(18): e3531-e3531.
［6］陈侃, 陈鹏飞, 王丹宁, 等. 高龄冠心病患者行PCI术后发生并发症的危险因素［J］. 中国循证心血管医学杂志, 2016, 8(4): 428-431.
［7］叶小春, 张耕, 陈霄. 经皮冠状动脉介入术后阿司匹林与氯吡格雷不耐受抗血小板方案选择［J］. 医药导报, 2017, 36(8): 940-941.
［8］Aycock KI, Campbell RL, Lynch FC, et al. The importance of hemorheology and patient anatomy on the hemodynamics in the inferior vena cava［J］. Ann Biomed Eng, 2016, 44(12): 1-15.
［9］Weissenberg K. Review: hemorheology, proceedings of the 1st international conference［J］. Biorheology, 2017, 7(2): 137-145.
［10］桂翔. 不同剂量比索洛尔治疗对冠心病心力衰竭患者心功能及T淋巴细胞亚群的影响［J］.热带医学杂志, 2018, 18(2): 216-220.
［11］余祖善, 徐丹蕾, 何义. 丹参多酚酸盐对急性冠脉综合征患者经皮冠脉介入术后心肌微循环与心功能的影响［J］. 中国药师, 2016, 19(1): 109-111.
［12］Dinicolantonio JJ, Lucan SC, O'Keefe JH. The evidence for saturated fat and for sugar related to coronary heart disease［J］. Prog Cardiovasc Dis, 2016, 58(5): 464-472.
［13］Kjaergaard AG, Dige A, Nielsen JS, et al. The use of the soluble adhesion molecules sE-selectin, sICAM-1, sVCAM-1, sPECAM-1 and their ligands CD11a and CD49d as diagnostic and prognostic biomarkers in septic and critically ill non-septic ICU patients［J］. APMIS, 2016, 124(10): 846-855.
［14］Lai JL, Liu YH, Liu C, et al. Indirubin inhibits LPS-induced inflammation via, TLR4 abrogation mediated by the NF-kB and MAPK signaling pathways［J］. Inflammation, 2017, 40(1): 1-12.
［15］Lewis MJ, Vyse S, Shields AM, et al. Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1［J］. Arth Res Ther, 2016, 18(1): 5-5.
［16］李原, 刘海莹. 中青年冠心病患者PCI术后支架内再狭窄发生情况及相关影响因素分析［J］. 空军医学杂志, 2017, 33(5): 330-332+336.
［17］林振宇, 陈雨. 阿司匹林与比索洛尔联合用药对冠心病经皮冠状动脉介入术后患者心脏康复的影响［J］. 临床和实验医学杂志, 2017, 16(16): 1629-1632.
［18］Zhang D, Wu J, Liu S, et al. Salvianolate injection in the treatment of unstable angina pectoris:A systematic review and meta-analysis［J］. Medicine, 2016, 95(51): e5692-e5692.
［19］Liu QQ, Han J, Zuo GY, et al. Potentiation activity of multiple antibacterial agents by Salvianolate from the Chinese medicine Danshen against methicillin-resistant Staphylococcus aureus, (MRSA)［J］. J Pharmacol Sci, 2016, 131(1): 13-17.
［20］van Campen JS, De BK, Mc VDV, et al. Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study ［J］. Eur Respir J, 2016, 48(3): 787-796.
［21］Trobec KC, Grabnar I, Kos MK, et al. Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study ［J］. Eur J Clin Pharmacol, 2016, 72(7): 813-822.
［22］Choi SW, Han S, Shim WJ, et al. Impact of heart rate reduction with maximal tolerable dose of bisoprolol on left ventricular reverse remodeling ［J］. J Korean Med Sci, 2018, 33(25): e171-e171.

[1]	QIAN Jin, WANG Fengyan. Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
[2]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[3]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Evinacumab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
[4]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Inclisiran [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
[5]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
[6]	CHANG Shufu . Progress of medical treatment of coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
[7]	WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming. Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
[8]	YAN Lei, JIANG Haibin, NAFEISHA Paerhati, REZIWANGULI Yikemu, GENG Boyu, MAIERHABA Maimaitiaili. Effects of different doses of dexmedetomidine on non-cardiac surgery stress and postoperative sleep in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1340-1346.
[9]	LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian. Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
[10]	PENG Qiuju, YAN Huacheng, SHI Lei. Advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 477-480.
[11]	WANG Weiyu, YU Hao. Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.
[12]	WEI Yuqiang. Protective effects of liraglutide on myocardium of AMI patients with the treatment of PCI [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 184-188.
[13]	ZHOU Jianhua, LIU Kelan, WU Ganbin. Effects of anti-platelet individual treatment guided by CYP2C19 polymorphism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1364-1367.
[14]	WANG Shiqi, HU Huawen, CHEN Xiaomin, WANG Jian, YE Honghua. Effects of different intensities of warfarin on patients with coronary atherosclerotic heart disease complicated with atrial fibrillation: a comparative study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1410-1414.
[15]	FANG Chao, ZENG Hui, ZHOU Hong-Hao, LIU Zhao-Qian. Research progress on relationship between eNOS and ACE gene polymorphisms and coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 222-228.